UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Carter P
(2022)
Coffee consumption and cancer risk: a Mendelian randomisation study.
in Clinical nutrition (Edinburgh, Scotland)
Carvalho-E-Silva AP
(2020)
Does type 2 diabetes increase the risk of musculoskeletal pain? Cross-sectional and longitudinal analyses of UK biobank data.
in Seminars in arthritis and rheumatism
Casanova F
(2021)
Higher adiposity and mental health: causal inference using Mendelian randomization.
in Human molecular genetics
Casanova F
(2022)
Simulated distributions from negative experiments highlight the importance of the body mass index distribution in explaining depression-body mass index genetic risk score interactions.
in International journal of epidemiology
Casanova F
(2019)
A genome-wide association study implicates multiple mechanisms influencing raised urinary albumin-creatinine ratio.
in Human molecular genetics
Cassidy S
(2018)
Accelerometer-derived physical activity in those with cardio-metabolic disease compared to healthy adults: a UK Biobank study of 52,556 participants.
in Acta diabetologica
Castaneda AB
(2022)
Associations of carotid intima media thickness with gene expression in whole blood and genetically predicted gene expression across 48 tissues.
in Human molecular genetics
Castela Forte J
(2021)
Development and Validation of Decision Rules Models to Stratify Coronary Artery Disease, Diabetes, and Hypertension Risk in Preventive Care: Cohort Study of Returning UK Biobank Participants.
in Journal of personalized medicine
Cavallo F
(2022)
Unsupervised Classification of Human Activity with Hidden Semi-Markov Models
in Applied System Innovation
Cavazos TB
(2022)
Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies.
in BMC medicine
Cecelja M
(2022)
Aortic Distensibility Measured by Automated Analysis of Magnetic Resonance Imaging Predicts Adverse Cardiovascular Events in UK Biobank.
in Journal of the American Heart Association
Celis-Morales CA
(2018)
Associations of Dietary Protein Intake With Fat-Free Mass and Grip Strength: A Cross-Sectional Study in 146,816 UK Biobank Participants.
in American journal of epidemiology
Celis-Morales CA
(2019)
Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality.
in Medicine and science in sports and exercise
Censin J
(2019)
Causal relationships between obesity and the leading causes of death in women and men
in PLOS Genetics
Cerani A
(2019)
Genetic predisposition to increased serum calcium, bone mineral density, and fracture risk in individuals with normal calcium levels: mendelian randomisation study.
in BMJ (Clinical research ed.)
Cetin I
(2020)
Radiomics Signatures of Cardiovascular Risk Factors in Cardiac MRI: Results From the UK Biobank.
in Frontiers in cardiovascular medicine
Chadalavada S
(2021)
Women With Diabetes Are at Increased Relative Risk of Heart Failure Compared to Men: Insights From UK Biobank.
in Frontiers in cardiovascular medicine
Chadeau-Hyam M
(2020)
Education, biological ageing, all-cause and cause-specific mortality and morbidity: UK biobank cohort study.
in EClinicalMedicine
Chai T
(2022)
Association of Circulating Cathepsin B Levels With Blood Pressure and Aortic Dilation.
in Frontiers in cardiovascular medicine
Chai T
(2022)
Genome-Wide Identification of Associations of Circulating Molecules With Spontaneous Coronary Artery Dissection and Aortic Aneurysm and Dissection
in Frontiers in Cardiovascular Medicine
Chakraborty S
(2022)
Exome-wide analysis reveals role of LRP1 and additional novel loci in cognition
Chambers T
(2022)
Genetic common variants associated with cerebellar volume and their overlap with mental disorders: a study on 33,265 individuals from the UK-Biobank.
in Molecular psychiatry
Chambers T
(2021)
Effects of Thyroid Status on Regional Brain Volumes: A Diagnostic and Genetic Imaging Study in UK Biobank.
in The Journal of clinical endocrinology and metabolism
Chami N
(2020)
The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK Biobank population.
in PLoS medicine
Chan LLY
(2022)
Development and large-scale validation of the Watch Walk wrist-worn digital gait biomarkers.
in Scientific reports
Chan M
(2021)
A Biomarker-based Biological Age in UK Biobank: Composition and Prediction of Mortality and Hospital Admissions
in The Journals of Gerontology: Series A
Chand G
(2022)
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population
in American Journal of Psychiatry
Chang H
(2022)
Environmental and cultural factors as concerns of depressive symptoms
in Brain, Behavior, and Immunity
Chang HC
(2023)
Antidepressant use, chronic inflammatory comorbidities and behavioral disinhibition.
in Brain, behavior, and immunity
Chang J
(2022)
Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study.
in Journal of translational medicine
Chang Y
(2022)
Neural network training with highly incomplete medical datasets
in Machine Learning: Science and Technology
Channa R
(2021)
Detecting retinal neurodegeneration in people with diabetes: Findings from the UK Biobank.
in PloS one
Chaplin AB
(2021)
Sexual and physical abuse and depressive symptoms in the UK Biobank.
in BMC psychiatry
Che B
(2022)
Multivitamin/mineral supplementation and the risk of cardiovascular disease: a large prospective study using UK Biobank data.
in European journal of nutrition
Cheesman R
(2020)
Comparison of Adopted and Nonadopted Individuals Reveals Gene-Environment Interplay for Education in the UK Biobank.
in Psychological science
Cheesman R
(2020)
Familial Influences on Neuroticism and Education in the UK Biobank.
in Behavior genetics
Chen BB
(2022)
Putative Candidate Drug Targets for Sarcopenia-Related Traits Identified Through Mendelian Randomization Analysis of the Blood Proteome.
in Frontiers in genetics
Chen C
(2020)
Improving the Generalizability of Convolutional Neural Network-Based Segmentation on CMR Images.
in Frontiers in cardiovascular medicine
Chen DC
(2023)
Differential Associations of Cystatin C Versus Creatinine-Based Kidney Function With Risks of Cardiovascular Event and Mortality Among South Asian Individuals in the UK Biobank.
in Journal of the American Heart Association
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |